RFK Jr. could prove a surprise boon for stem-cell stocks with pivotal year ahead
Stem-cell research is on the cusp of a breakthrough that could come as soon as 2025, and two biotech companies with promising therapies stand to gain, according to a new report from Maxim Group on ...
Nature9d
CRISPR genome-editing grows up: advanced therapies head for the clinic
Gene-editing technologies for cancer and blood disorders are maturing a little more than a year after the first CRISPR drug ...
Business Wire1mon
GIOSTAR Announces FDA Clearance of the IND for Starting PHASE-2 Clinical Trial for Developing Specific Stem Cell Therapy for Type II Diabetes.
SAN DIEGO--(BUSINESS WIRE)--Global Institute of Stem Cell Therapy and Research, Inc. known as GIOSTAR, a San Diego, California based Global organization at the forefront of stem cell research over ...